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As the gap between donors and patients in need of an organ transplant continues to widen, research in regenerative medicine
seeks to provide alternative strategies for treatment. One of the most promising techniques for tissue and organ regeneration
is decellularization, in which the extracellular matrix (ECM) is isolated from its native cells and genetic material in order to
produce a natural scaffold. The ECM, which ideally retains its inherent structural, biochemical, and biomechanical cues, can
then be recellularized to produce a functional tissue or organ. While decellularization can be accomplished using chemical and
enzymatic, physical, or combinative methods, each strategy has both benefits and drawbacks. The focus of this review is to compare
the advantages and disadvantages of these methods in terms of their ability to retain desired ECM characteristics for particular
tissues and organs. Additionally, a few applications of constructs engineered using decellularized cell sheets, tissues, and whole
organs are discussed.

1. Introduction
Tissue and organ failure is currently one of the biggest
health issues our society faces. Arising from disease or
trauma, complete treatment typically requires the reparation
or replacement of the affected organ. Conventional practices
utilize organs from either live or deceased donors for the
procedure of transplantation. However, the deficit between
donors and patients requiring a new organ has grown
substantially in recent years, so much that there are more
than 100,000 patients on waiting lists for organs in the
United States alone [1]. This epidemic has led researchers to
explore alternative methods of treatment, in particular tissue
engineering, which seeks to reduce organ specificity and thus
alleviate the necessity for organ donation.
Tissue engineering aims at replacing or regenerating
human tissues or organs in order to restore or establish
normal function [2]. The tissue engineering triad consists of
three main factors, the cells, signaling molecules, and scaffold, which support and rely upon one another. Specifically,
the scaffold, together with integrated signaling molecules,
provides structural, biochemical, and biomechanical cues to

guide and regulate cell behavior and tissue development.
Scaffolds can be prepared through a variety of methods and
materials, both synthetic and natural. Synthetic scaffolds are
beneficial in that their structure and mechanical properties
can be manipulated and controlled with the goal of producing
an optimal environment for a particular cell type or cell
set. Among these properties, matrix stiffness and topography
show profound influences on cell growth and differentiation.
Stiffer polymers like poly(lactic-co-glycolic acid) (PLGA)
have been used in cartilage and bone tissue engineering
[3, 4], while softer hydrogels, benefitting from their tunable
mechanical properties and adjustable composition, have been
used for soft tissues [5]. Interestingly, differentiation towards
a desirable lineage can be facilitated on a matrix having
stiffness similar to that of the natural tissue [6, 7]. The
nanotopography of the scaffold also plays an important
role in cell regulation. In addition to inducing pronounced
changes to cell morphology and gene expression [8–11],
nanotopography can regulate the differentiation of stem cells
into certain lineages such as neuron [8, 12, 13], muscle
[14], and bone [15, 16]. Thus, cell behavior can be regulated through tailoring the scaffold’s properties. Technologies
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Figure 1: Process of engineering tissues using decellularized ECM.

like electrospinning and 3D printing enable the control
of these properties through optimization in the materials
and processing parameters. Electrospun constructs, which
consist of arranged polymeric nanofibers, have been utilized
in engineering several tissue structures, including vascular
grafts [17], bone [18], and myocardium [19]. Furthermore,
3D printing in scaffold design allows for the integration of
features like vasculature [20, 21] and the control of scaffold
architecture [22], using synthetic polymers or bioinks. These
methods show great promise in their ability to control key
properties of scaffolds and to subsequently manipulate cell
behavior for tissue engineering.
Because many challenges are associated with preparing
synthetic scaffolds that recapitulate the complexity of the
cell microenvironment, there has been increasing interest in
utilizing naturally derived extracellular matrix (ECM) itself.
This biologic scaffold is obtained through the process of
decellularization. The ultimate goal of decellularization is
to rid the ECM of native cells and genetic materials such
as DNA while maintaining its structural, biochemical, and
biomechanical cues. The decellularized ECM can then be
repopulated with a patient’s own cells to produce a personalized tissue. Decellularized ECM has been successfully used to
recreate various types of tissues and organs including blood
vessel [23–25], heart valve [26, 27], cornea [28–30], trachea
[31], esophagus [32], urinary bladder [33], kidney [34, 35],
liver [36–39], lung [40, 41], and heart [42, 43].
Figure 1 outlines the overall process of developing engineered tissues or organs from decellularization to recellularization. In the decellularization process, chemical and
enzymatic, physical, or combinative methods are utilized to
remove cells and DNA from the tissue while preserving its
structural and regulatory proteins. To assess the quality of
decellularized ECM, four aspects of the ECM are measured:

removal of cells, elimination of genetic material, preservation
of protein content, and retention of mechanical properties.
Cell and genetic material removal is critical in preventing
immunorejection of the construct to seeded cells. The criteria
for assessing the efficacy of removal of these components is
suggested as follows: the decellularized ECM must have (1)
less than 50 ng double-stranded DNA (dsDNA) per mg ECM
dry weight, (2) less than 200 bp DNA fragment length, and (3)
no visible nuclear material by 4 ,6-diamidino-2-phenylindole
(DAPI) staining [44]. Additionally, protein content remaining in the ECM should be evaluated, with emphasis on the
structural proteins like collagen, fibronectin, and laminin;
glycosaminoglycans (GAGs); and growth factors. Moreover,
the mechanical properties including elastic modulus and
tensile strength, depending on the application, should match
the original tissue. In this review, decellularization strategies
are evaluated based upon their efficacy in these four areas,
in addition to the toxicity and overall efficiency of the
technique, followed by a few applications of decellularized
ECM.

2. Decellularization Strategies
Decellularization has been performed through chemical,
physical, or combinative methods. An evaluation of these
strategies will first focus on the removal of cells and genetic
material followed by the maintenance of structural proteins.
In addition, mechanical properties and ultrastructure of the
tissue or organ before and after treatment will be compared. Emphasis will be placed upon the method’s ability to
retain the characteristics necessary for successful recreation
of the tissue or organ. Table 1 summarizes the chemical
and enzymatic agents and mechanical techniques used for
decellularization.

BioMed Research International

3
Table 1: Summary of decellularization agents and techniques.

Category

Agents and techniques
(1) Surfactants

Mechanism/description
Lyse cells by disarranging the
phospholipid membrane

(i) Cytotoxic: requires extensive
wash process
(ii) Alters microstructure (i.e.,
collagen fibers)

Sodium dodecyl sulfate
(SDS)

(i) Ionic

Triton X-100

(i) Nonionic
(ii) Commonly used with
ammonium hydroxide
(i) Ionic

Sodium deoxycholate (SD)
(ii) Commonly used with DNase
CHAPS

Chemical and
enzymatic

Mechanical

Significant effects

(i) Zwitterionic

(i) Less damaging to structure of
tissue than ionic surfactants
(i) Causes agglutination of DNA
when used without DNase
(ii) Remnant DNA fragments
(i) Maintains structural ECM
proteins
(ii) Remnant cytoplasmic proteins
(iii) Maintains ultrastructure

Solubilize cell membrane by utilizing
charged properties
(i) Highly corrosive
(i) Insufficient cell removal
Peracetic acid
(ii) Oftentimes used for sterilization (ii) Increases stiffness of ECM
Ethylenediaminetetraacetic
(i) Decreases salt- and acid-soluble
(i) Commonly used with trypsin
ECM proteins
acid (EDTA)
(i) Induces negative charge on
collagen to cause swelling
Reversible alkaline swelling
(i) Alters mechanical properties
(ii) Used with tridecyl alcohol
ethoxylate
Typically used to supplement other
(3) Enzymes
chemical & mechanical treatments
(i) Breaks cell-matrix adhesions
Trypsin
(ii) Commonly used with EDTA
Deoxyribonuclease
(i) Breaks down DNA fragments
(DNase)
(ii) Commonly used with SD
Ribonuclease (RNase)
(i) Breaks down RNA fragments

References

[45]
[46, 47]
[34, 48]
[49]
[45, 49–51]
[40]
[40]
[40, 41]

(2) Acids and bases

High hydrostatic pressure
(HHP)

(i) Pressures greater than 600 MPa
applied to lyse cells

Supercritical carbon
dioxide

(i) Applies CO2 at pressures above
7.40 MPa and temperatures above
31.1∘ C

Freeze-thaw

(i) Alternate between freezing
temperatures (−80∘ C) and
biological temperatures (∼37∘ C)

2.1. Chemical and Enzymatic Approaches. Several types of
chemicals have been used in decellularization, including
surfactants, acids, and bases. Surfactants, the most common
decellularizing agents, typically work by lysing cells through
disarranging the phospholipid cell membrane [57]. These
agents are classified based upon their charge, as they are
ionic, nonionic, or zwitterionic. Acids like peracetic acid and
bases like sodium hydroxide solubilize the cell membrane

(i) Remnant DNA fragments
(ii) Denatures ECM proteins
(i) Requires entrainer to remove
polar phospholipid membrane
(ii) Maintains ECM proteins &
mechanical properties
(i) Maintains ECM proteins &
mechanical properties
(ii) Remnant DNA

[45]
[45, 52]
[53]

[48]

[23, 28]
[23]
[54]
[54]
[55, 56]
[55]

and nuclear material by utilizing their intrinsically charged
properties.
2.1.1. Surfactants. The widely used ionic surfactant, sodium
dodecyl sulfate (SDS), has been successful in a number
of applications in decellularization because of its ability to
efficiently remove cells and genetic material. For example, it
was the major agent used in the whole rat heart perfusion
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decellularization [42]. SDS treatments have met the standard
requirements of complete cell removal and elimination of at
least 90% of host DNA in several types of tissues and organs,
including rat forearm [58], porcine cornea [30], porcine
myocardium [59], porcine heart valve [47], porcine small
intestine [45], porcine kidney [34], human vein [60], rat,
porcine, and human lungs [40, 46], and human heart [61].
Administering SDS to whole organs via perfusion allowed for
the maintenance of ultrastructure. Specifically, continuously
perfusing the solution through the vasculature not only
preserved the structure of the blood vessels but also helped to
prevent the deformation of alveoli [40]. This aspect was vital
for the nourishment of seeded stem cells [62] and ultimately
for the recovery of the organ’s original function.
Although SDS can successfully remove unwanted native
constituents of the tissue, it can be damaging to the structural and signaling proteins. For instance, the collagen in
SDS-treated heart valves became compacted [47], and the
decellularized ECM of human and porcine lungs appeared
more fibrous than the structure of the smooth native tissue
[46]. The fibrous structure of human hearts decellularized
using SDS; however, it was not affected, as the anisotropic
properties resembled those of native myocardium [61]. GAGs
and growth factors like vascular endothelial growth factor
(VEGF) were also diminished by SDS treatment, which can
affect the biochemical cues regulating cell function. Such
a decrease in GAGs, however, was likely a result of the
location of these molecules in the cell membrane, which was
destroyed in the decellularization process [39]. Damaging
structural proteins and components not only can prevent the
cells from inhabiting the tissue as before but also prevents
the full retention of its mechanical properties. This result
is particularly prevalent in thinner tissues and cell sheets.
After being treated with a 0.5 wt% SDS solution, fibroblast
cell sheets showed an 80% decrease in elastic modulus [55].
As the SDS concentration increased, the elastic and viscous
moduli decreased, indicating the damaging nature of SDS.
In the case of decellularized porcine myocardium, the tissue
became stiffer, as the tensile strength was twenty times greater
than the native tissue [59]. However, because collagen type IV
was maintained, the tissue exhibited extensibility, a property
critical for its desired function as a cardiac patch. SDS is
also cytotoxic; therefore, it is imperative that the tissue is
thoroughly washed to ensure the viability of reseeded cells
[45]. While most surfactant-treated tissues must typically
be washed with solutions like phosphate buffered saline
(PBS), SDS is more difficult to remove due to its ionic
nature. The required extensive wash process following treatment is another disadvantage of SDS as a decellularizing
agent.
The nonionic surfactant Triton X-100 is oftentimes utilized to remove the remnant SDS. This practice has been
especially prevalent in the perfusion decellularization of
whole organs [39, 40, 42, 45, 58, 61]. Not only is Triton X100 beneficial in the wash process, but also it is commonly
used as a decellularizing agent alone. As it is nonionic,
it is less harsh than SDS and ultimately less damaging to
the structural integrity of the tissue. In conjunction with
ammonium hydroxide, it completely removed all DNA and
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maintained a greater amount of collagen I compared to
SDS treatments [34]. Additionally, the tissue’s ultrastructure
and mechanical properties were well preserved following the
decellularization process [48].
Sodium deoxycholate (SD) is another ionic surfactant
that works by solubilizing the cell membrane. Unlike SDS, SD
produced scaffolds that were highly biocompatible, as cells
seeded on the SD-decellularized matrices exhibited higher
metabolic activity compared to those decellularized via SDS
[45]. Complete cell removal by using SD was observed in a
perfusion treatment of rat lungs [40], as well as an agitation
treatment of porcine heart valve leaflets [47]. Although SD is
nondamaging, it can cause the agglutination of DNA on the
tissue’s surface [49]. To address this issue, a 4% SD solution
was combined with the enzyme, deoxyribonuclease I (DNase
I), to break down the tissue’s native DNA. This particular
protocol was used for a variety of structures including blood
vessels [49, 63], tracheas [50, 64], diaphragm [65], aortic
root [66], and small intestines [45, 51]. However, despite the
fact that the function of DNase I is to break down DNA
fragments, a significant amount of DNA remained in the
ECM following treatment [45, 49–51, 66]. As a result, more
extensive wash processes must be performed in order to
eliminate DNA present in the tissue to prevent immunorejection. Additional treatment cycles have also been shown
to eliminate a greater percentage of DNA, as was the case
in the decellularization of the diaphragm, which exhibited
a 95% decrease in native genetic material after three cycles
[65]. In addition, structural proteins such as fibronectin and
laminin were retained, and the position of collagen fibers
was preserved in the treatment of porcine and rat tracheas
[50, 64], as well as the rat diaphragm [65]. This property is
important for the trachea, in particular, since its shape and
structure affect the resistivity of the airway. In addition to
ECM proteins, von Willebrand factor was found to be present
in the decellularized aortic root, a protein key to maintaining
hemostasis, and the mechanical properties remained similar.
However, lower peak pressures were observed, signifying
an alteration in valve closure functioning. Furthermore, the
compliance of the tissue was maintained in the SD/DNase I
treatment of blood vessels, which is crucial for their ability
to contract and dilate [63]. In the case of decellularized
lungs, a greater amount of myosin was retained when using
SD compared to that with other surfactant treatments [40],
and collagen and elastin were well preserved in the heart
valve leaflets [47]. The muscle fiber arrangement and collagen
fiber alignment in the diaphragm remained following three
SD/DNase cycles, which enabled similar mechanical function
to native tissue [65]. These results highlight the ability of
SD to retain the structural proteins necessary for the tissue’s
function.
The zwitterionic, nondenaturing detergent, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS),
has been applied in both immersion and perfusion decellularization procedures. Human- and porcine-derived lung
tissues [40, 46] and rat lungs [40, 41] were treated with 8 mM
CHAPS solutions, each exhibiting complete decellularization
by the histological analysis. However, cytoplasmic proteins
remained, indicating that not all cellular debris was removed
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[40]. ECM proteins like collagen and elastin were preserved,
thereby allowing the lung tissue to retain its compliance.
This aspect was likely due to the nondenaturing properties of
CHAPS, which are highly beneficial in lung applications due
to the requirement that the tissue expand and contract with
ease. The ultrastructure of the lung, airways, and vasculature,
as well as the structure of the alveoli, was retained in
whole lung experiments [40, 41]. While CHAPS excelled
in the areas of protein and structural maintenance, other
detergents like SDS tended to demonstrate greater efficiency
in reducing the level of residual DNA. Thus, further wash
steps to eliminate the immunogenic potential of the tissue
treated with CHAPS may improve the overall efficacy of this
detergent.
2.1.2. Acids and Bases. Acid- and base-containing protocols
utilize agents like peracetic acid and techniques like reversible
alkaline swelling. Peracetic acid is a highly corrosive and
strong oxidizer oftentimes used for sterilization. Thinner
tissues such as the small intestine submucosa (SIS) [45] and
urinary bladder [52] have been treated with peracetic acid as
a decellularizing agent. While it was shown that the SIS was
biocompatible following treatment, the cells were not entirely
removed [45]. In addition, the mechanical properties of the
tissue were altered with a significant increase in yield stress
and elastic modulus, particularly in the longitudinal rather
than circumferential direction. A similar effect was observed
in the treatment of urinary bladder matrix and submucosa,
as a stiffer ECM was produced in the longitudinal direction
resulting from differences in collagen fiber alignment [52].
These results imply an alteration in function of the tissue
following peracetic acid treatment, which indicates that its
use may not be suitable for tissues in which expandability and
compliance are desired properties. In another study regarding
the decellularization of bovine pericardium, tridecyl alcohol
ethoxylate, a nonionic surfactant, was used by itself and
with a calcium oxide alkaline solution [48]. Used alone, the
tissue was completely void of cells and the viscoelasticity
and ultrastructure remained the same. With the addition
of the alkaline solution, swelling resulted from the induced
negative charge on collagen in the tissue, which was subsequently reversed with ammonium sulfate. While this protocol
similarly eliminated cellular and genetic material and maintained the ultrastructure of the tissue, the swelling caused
a reduction in the tissue’s GAG content and viscoelasticity.
Thus, it was ultimately harsher than the tridecyl alcohol
ethoxylate alone and provided no significant benefits in terms
of reducing immunogenicity.
2.1.3. Enzyme-Assisted Decellularization. Like the use of
DNase I to prevent the agglutination of DNA in SD treatments, other types of enzymes have been used in decellularization protocols to supplement the chemicals’ properties.
For example, Triton X-100 and SD were used in combination
with DNase in the decellularization of both normal and
emphysematous human lungs [67] and porcine heart valves
[68] in order to break down remnant DNA fragments so
as to limit potential immunogenicity in vivo. A perfusion
and immersion approach was utilized in the lung treatment
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[67]. Collagens type I and IV, fibronectin, and laminin were
maintained; however, the GAG content was significantly
lower following treatment. While the functional smooth
muscle proteins, myosin and actin, were preserved, elastin
decreased. The overall ultrastructure of the lung, including
the alveolar septum, was maintained. In the decellularization
of the heart valves, a three-day wash cycle was performed,
and the decellularized ECM subsequently underwent enzymatic digestion with both DNase and RNase [68]. Cellular
debris was fully eliminated and collagen and elastin were
maintained. Another detergent-enzymatic treatment involving the use of an SDS/SD solution and endonuclease for
equine carotid artery decellularization highlighted potential complications that may arise with xenogeneic scaffolds
[69]. While no visible nuclei were observed and DNA was
significantly reduced following treatment, several antibodytriggering proteins remained. The presence of these distinguishing factors indicated failure to reduce the scaffold’s
immunogenicity and, therefore, to produce a universally
compatible matrix. In addition, the amount of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a glycolytic
enzyme, and smooth muscle actin decreased with the SDS/SD
endonuclease treatment. Another multistep protocol utilized
trypsin/ethylenediaminetetraacetic acid (EDTA), SDS, Triton X-100, peracetic acid/ethanol, and DNase to decellularize
porcine rectus abdominis muscle [70]. Cells and DNA were
sufficiently removed and laminin, collagen type IV, and
fibronectin remained following treatment. Additionally, the
decellularized muscle displayed mechanical strength similar
to the native muscle. The ultrastructure, vasculature, and
neural channels were intact as well.
Trypsin is an enzyme commonly used with EDTA which
works by breaking the cell-matrix adhesions. Used in the
treatment of porcine pulmonary valves, complete cell and
genetic material removal was observed after 24 hours [53]. At
shorter treatment times, particularly at eight hours, the cell
removal was incomplete. A longer treatment time, however,
led to decreased GAG, collagen, and elastin content and,
subsequently, mechanical strength. In addition, due to the
properties of trypsin/EDTA, the salt- and acid-soluble collagens were poorly preserved. Because of the inefficiency of
trypsin/EDTA-only treatment, several of the aforementioned
detergents have been combined in certain protocols. In
another study of porcine heart valve decellularization, the
tissues were treated with Triton X-100 and DNase and RNase
following trypsin/EDTA exposure [47]. Cell nuclei did not
remain and elastin fibers were preserved intact. Collagen
fibers, on the other hand, deformed, a result which can be
detrimental to the heart valve’s structural function. In porcine
trachea decellularization, trypsin was supplemented to the
SD/DNase I in a five-cycle protocol [71]. Each cycle involved
the addition of 1% trypsin (3 hr at 4∘ C), 4% SD (4 hr at
room temperature), and DNase I (3 hr at room temperature)
with wash cycles in between each new solution. No cellular
debris remained and collagen and elastic properties were
maintained. The most significant result of this decellularization treatment was the elimination of chondrocytes,
which was likely due to the trypsin breaking down the
chondronectin fibers in the trachea’s cartilage. Many other
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treatments involving this structure have been unsuccessful
in this regard [50, 64]. Therefore, chemical approaches can
be improved by combining them with enzymatic treatments
that may remove the unwanted cellular and genetic components of the ECM. However, their efficacy is ultimately
dependent upon the maintenance of ECM features that are
critical in regenerating the desired function of the particular
tissue.
2.2. Mechanical Approaches. While chemical and enzymatic
approaches are the most widely applied decellularization
methods, there are concerns regarding the possible toxicity
of the chemicals and destruction of ECM proteins. Other
methods that can physically or mechanically decellularize
the ECMs are therefore being developed. These methods
include temperature and pressure treatments that work to
eliminate cells through a combination of lysing the cells
and destroying cell-matrix adhesive proteins. In particular,
physical treatments include the use of freeze-thaw, high
hydrostatic pressure, or supercritical carbon dioxide (CO2 ) to
fully remove a tissue’s constituent cells and genetic materials.
While each specific method is unique, every mechanical
decellularization protocol involves a wash process to remove
any cellular debris that may remain. In many cases, the
washing step is critical in determining the efficacy of the
procedure.
2.2.1. Freeze-Thaw. Freezing and thawing tissues lyses, and
subsequently eliminates, the cells to produce a decellularized matrix. Freeze-thaw procedures oftentimes involve
alternating between freezing temperatures around −80∘ C
and biological temperatures around 37∘ C. Specific protocols
can be altered by increasing the temperature difference or
changing the number of freeze-thaw cycles performed. Two
particular freeze-thaw studies involved the decellularization
of fibroblast cell sheets carried out with three cycles [55] and
canine lumbar spinal segments carried out with one cycle
[56]. In both instances of freeze-thaw, the collagen and GAG
content, as well as the mechanical strength, were similar
to those of the native specimen [55, 56]. However, 88% of
the DNA in the fibroblast cell sheets remained following
treatment [55]. These results indicate that the ECM scaffold
resulting from this procedure may produce an immunogenic
response in vivo. Therefore, although freeze-thaw procedures
are beneficial in their retention of biochemical components
and biomechanical properties, they can potentially lead to
immunorejection due to the insufficient removal of genetic
materials.
2.2.2. High Hydrostatic Pressure. High hydrostatic pressure
(HHP) has become an increasingly prevalent method that
applies pressures greater than 600 MPa to destroy cell membranes. In one study, porcine corneas were decellularized
using HHP at 980 MPa for 10 minutes at 10 or 30∘ C [28]. The
same procedure was also carried out on porcine blood vessels
[23]. In both tissues, the high-pressure treatment destroyed
the cells, yet it left behind DNA remnants. Because HHP
alone failed in this regard, the wash solutions utilized in
both studies contained DNase I to break down fragments
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in order to prevent immunorejection [23, 28]. The cornea
wash solution also contained the glucose polymer, dextran,
in order to reduce swelling caused by the submersion in the
solution [28]. Glycerol was added in order to help maintain
its transparency and elastic moduli, two properties crucial to
the cornea’s function in the eye.
Difference in the temperature can lead to alterations in
protein content and structure. At 10∘ C, both collagen and
GAG content were better maintained in the cornea decellularization than at 30∘ C [28]. However, ice formation occurred at
10∘ C at HHP, which led to the destruction of tissue structure
[23]. Furthermore, the high pressure itself was shown to
denature ECM proteins, as observed in the deformation of
collagen and elastin fibers in the decellularized blood vessels
and consequently the decrease in ultimate tensile strength
by approximately 50% [23]. Therefore, although HHP treatment is beneficial in its short treatment time and ability to
sterilize the tissue through its destruction of bacterial and
viral membranes, it requires an extensive wash process and
can alter the structural and mechanical properties of the
tissue.
2.2.3. Supercritical Carbon Dioxide. With the unique transport properties, that is, a liquid-like density and a gas-like
diffusivity, supercritical fluids have been used in extraction
applications in industry [72–74]. In particular, supercritical
CO2 has a critical temperature of 31.1∘ C and a critical
pressure of 7.40 MPa, which is biologically permissive. Hence,
supercritical CO2 has been used in the decellularization of
aortic tissue, where the tissue was treated at 15 MPa and 37∘ C
[54]. Moreover, due to the diffusivity of CO2 , the solvent can
be quickly released and does not remain within the tissue,
preventing the need for extensive wash procedures usually
required for the processes involving surfactants. Because
CO2 is nonpolar, ethanol was added as an entrainer to
remove the polar phospholipid cell membranes. This addition
proved effective, since neither the cell nucleus nor membrane
remained in the tissue after treatment. Collagen and elastin
content, and subsequently mechanical strength, were not
altered with treatment, demonstrating the nondeforming
capabilities of supercritical CO2 .
2.3. Combined Methods. Because each aforementioned technique has its advantages and disadvantages, several techniques have been combined to complement one another with
the goal of retaining desired characteristics in the engineered
tissue. For example, mechanical methods are typically less
damaging to the tissue’s structure; however, they fail to meet
the requirements for immunogenicity. On the other hand,
surfactants at low concentrations or enzymes used alone may
not completely remove all cellular debris. To this regard,
combining the two treatments in a multistep process can
yield a decellularized ECM appropriate for its particular
application. While the combined method may demand more
chemicals and a longer processing time than single-treatment
protocols, each constituent parameter needs to be optimized
to suit a particular tissue. These tissue-specific protocols can
thus be more practical and effective.
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Thicker tissues, in particular those composed of multiple
layers, oftentimes require multistep decellularization procedures involving chemical, enzymatic, and mechanical treatments. Adipose, or fat tissue, is one type of thick tissue and is
desired in reconstructive surgeries. While its characteristics
are simple compared to more complex tissues such as lung or
heart, it is necessary to maintain adipose tissue’s mechanical
properties and biochemical factors in order to regulate
adipogenesis. In one particular method, a multistep process
was carried out on porcine adipose tissue [75]. The procedure
began by mechanically massaging the tissue while it was
frozen to facilitate cell removal. The tissue then underwent an
enzymatic treatment of trypsin/EDTA and surfactant treatments of Triton X-100 and SD. It was sterilized using ethanol
and peracetic acid, and polar remnants were solubilized using
n-propanol. Following the 16-step treatment, complete cell,
DNA, and lipid removal was observed. Additionally, both
collagen type IV and laminin fibers were maintained, as was
the majority of the GAG content. While this process damaged
collagen I fibers and reduced the levels of vascular endothelial
growth factor (VEGF) and transforming growth factorbeta (TGF-𝛽), the tissue did facilitate adipogenesis. Another
treatment of adipose tissue involved a five-day process of
multiple freeze-thaw cycles and alternating between two different enzymatic digestion solutions (one containing trypsin
and the other containing DNase II, RNase III, and lipase
IV), in addition to polar solvent extractions [76]. Cellular
debris was completely removed throughout the tissue, and
laminin and collagen I fibers were maintained. In addition,
part of the vasculature remained, which would aid in the
recellularization and vascularization of the reconstructed
tissue.
Multistep chemical, enzymatic, and mechanical combinative methods have been proven to be detrimental to different
properties of some tissues. In a protocol involving the
treatment of porcine cartilage disks, two different hypotonic
buffers were used, the first supplemented with 100 mM KCl,
5 mM MgCl2 , and 100 mM dithiothreitol (DTT) and the
second supplemented with 0.5% SDS, in order to solubilize
the cell membranes [77]. The tissue was then subjected to
hyaluronidase to increase its porosity, as well as alternating
cycles of freeze-thaw and a nuclease digestion. To further
increase porosity, the tissue also underwent sonication in
sodium hydroxide. Creating a more porous scaffold was
desired in order to aid in DNA removal and subsequent
recellularization. The method was effective in removing a
majority of cells and DNA, as well as maintaining collagen
and ultrastructure of the tissue. However, several mechanical
properties decreased as a result of increased porosity. In
the treatment of whole rat lungs, two different mechanical
methods were utilized in combination with surfactants and
enzymes [78]. Four freeze-thaw cycles were performed; then
the lungs were placed in a continuously circulating bioreactor
with 1% SDS. After five weeks, the lungs were removed and
treated with a nuclease digestion. Characterization of the
resultant ECM revealed the absence of cellular debris and
the maintenance of a majority of the collagen and elastin
content. Collagen type I fibers, however, no longer had the
same fibrous pattern, and collagen type IV, laminin, and
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fibronectin were significantly reduced. Such a difference in
ECM composition was likely due to the large amount of time
the lungs underwent treatment.

3. Assessment of Decellularization
3.1. Immunogenicity. Reducing the scaffold’s immunogenicity is one of the most critical requirements of decellularization. This particular aspect has been crucial in preventing the
use of decellularized ECM as scaffolds in clinical applications.
Ideally, xenogeneic scaffolds may be used, as they are highly
abundant and thus have the potential to be manufactured.
If their immunogenicity is not sufficiently reduced, they
may be rejected in vivo, leading to functional failure and
the need for immediate replacement or removal. The two
components capable of inducing an immunogenic response
include remnant genetic materials such as DNA and RNA
and antigens. In terms of eliminating genetic materials, Crapo
and colleagues have suggested that the decellularized ECM
should contain less than 50 ng dsDNA per mg ECM and DNA
fragment lengths less than 200 bp [44]. Detergents including
SDS and Triton X-100 have met the first criterion, as they
remove greater than 90% of remnant DNA [30, 34, 40, 45–47,
58, 60]. Other detergents such as SD and CHAPS, however,
are less successful in this regard [40, 41, 45, 49–51]. For
the second criterion, endonucleases including DNase and
RNase have been used to break down nucleic acid fragments.
While these enzymes successfully reduce the length of fragments and subsequently prevent significant immunogenic
responses, they do little to separate the fragments from the
ECM. Furthermore, mechanical approaches including the
use of freeze-thaw and HHP left behind DNA remnants,
suggesting the need for more extensive wash procedures
[23, 28, 55].
Native antigens must also be reduced in the scaffolds to
prevent immunorejection. Hyperacute rejection of scaffolds,
occurring shortly after implantation and caused by circulating antibodies within the host, and acute immune rejection,
occurring days to weeks after implantation, are of particular
concern [79]. This aspect is oftentimes not considered in
decellularization; however, it is critical to analyze the presence
of triggering entities prior to implantation in vivo. Specific
components that may be measured include alpha-gal epitopes
which have the potential to activate the complement cascade immune response and major histocompatibility (MHC)
complexes present on the cell membrane, which can lead
to T cell and natural killer cell responses [79]. While these
are immunogenic molecules that provide primarily adverse
effects to the host, ECM structural proteins like collagen
VI have indicated potential immunogenicity [80]. Thus,
while these proteins are desired to maintain the structure
and mechanical properties of the engineered construct, they
may be overtly specific to their native organism. Additional
strategies to limit their immunogenic effect, in particular
recellularizing the ECM with autologous cells, are therefore
necessary to prevent host rejection.
3.2. Mechanical Properties. In regenerating a tissue or
organ via decellularization, maintaining the mechanical
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characteristics of the native tissue is of vital importance in
ensuring proper functionality. Primary properties of interest
include elastic modulus, viscous modulus, tensile strength,
and yield strength; however, the most crucial properties
ultimately depend on the nature of the tissue or organ’s
desired function. In particular, stiffness is desired in the
design of a trachea to provide an unobstructed airway.
Furthermore, the anisotropic or isotropic characteristics of
the tissue are also necessary to modulate, as they can
oftentimes dictate the orientation of reseeded cells: such is
the case with cardiomyocytes in myocardium regeneration
[81]. These properties are primarily governed by the ECM
structural proteins collagen, laminin, fibronectin, and elastin.
Each decellularization strategy produces different effects on
these proteins; therefore, the technique used must be chosen
based upon the tissue biomechanics necessary for proper
function.
Both chemical and mechanical methods have been shown
to damage the structural proteins of the ECM. In particular,
SDS has been shown to alter the ECM’s microstructure by
causing collagen to become compacted [47] and producing a
more fibrous matrix [46]. More pronounced changes in the
structure and mechanical properties tend to be correlated
with increased concentrations of the detergent. This effect was
observed in the decrease in elastic modulus of fibroblast cell
sheets treated with SDS [55]. Other detergents like Triton X100, SD, and CHAPS, however, sufficiently maintained key
ECM proteins and mechanical properties. Additionally, acids
and bases have been shown to alter the compliance of tissues,
as peracetic acid increased the elastic modulus of the SIS and
bladder [45, 52] and reversible alkaline swelling decreased
the viscoelasticity of bovine pericardium [48]. The amount
of time the tissue is exposed to the decellularizing agent also
plays an important role in damaging the structural proteins.
In particular, porcine pulmonary valves treated with EDTA
and trypsin exhibited a decrease in mechanical strength at
longer treatment times, which were necessary for complete
cell removal [53]. This effect is likely a result of changes
in collagen content and fiber orientation, as EDTA has
been shown to diminish salt- and acid-soluble collagens [47,
53]. Mechanical treatments better maintain these properties;
however, the parameters at which the treatments are carried
out must be optimized accordingly. Freeze-thaw treatments
sufficiently preserve the mechanical strength of the original
tissue [55, 56]; however, this may be impacted by further
cycles. High hydrostatic pressure has a risk of denaturing
ECM proteins [23]. In addition, when performed at lower
temperatures, ice may form within the tissue, thus leading
to greater deformation. Therefore, exposure to each of these
treatments must be performed under the mildest conditions
necessary to fully decellularize and remove immunogenic
constituents of the ECM.

4. Recellularization
Recellularization of the decellularized ECM must also be
optimized in order to produce a functional tissue or organ.
The cell type used to repopulate the matrix and method of
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recellularization is largely dependent on the complexity of
the cell sheet, tissue, or organ of interest. Cell sheets for skin
grafts or blood vessels may only require a single cell type,
whereas whole organs such as the heart or liver necessitate the
seeding of multiple cell types. Furthermore, recellularization
of cell sheets can be accomplished by simply applying the
cell suspension onto the monolayer surface, and threedimensional constructs can be created through alternating
between the cell suspension and additional cell sheets as
in the “sandwich model” for cartilage construction [82, 83].
Multilayer tissues such as the colon may be separated in
order to expose individual layers for precise injection [84]. In
addition, sonication has been utilized to facilitate cell seeding
through inducing pore formation within the tissue [77, 85].
For thicker tissues and whole organs, however, the cells may
be injected directly into the tissue or perfused through the
vasculature of the construct. The latter method is especially
beneficial following perfusion decellularization in which
detergent solutions are pumped directly into the vasculature
for a given period of time [38, 39, 42]. Additionally, reendothelializing the vasculature of decellularized constructs has
also been shown to improve the organization of seeded cells.
For example, endothelial cells were reintroduced via the aorta
only, the brachiocephalic artery (BA) only, or both the aorta
and BA of a decellularized rat heart prior to the introduction
of cardiomyocytes, which increased their contractibility [43].
The combined approach proved to be more effective in
endothelializing the vasculature and subsequently limited
its thrombogenicity. The bioreactor environment has also
been shown to influence the success of recellularization,
as a rotating wall vessel bioreactor facilitated greater cell
proliferation and viability of two different cell types seeded
within decellularized mouse lungs over static conditions [86].
Furthermore, acellular scaffolds may be introduced into the
body so that autologous cells may naturally repopulate the
ECM.

5. Applications
Decellularization has been performed on a variety of cell
sheets, tissues, or organs, depending on the necessary replacement or regenerative treatment. Table 2 highlights decellularization strategies most commonly employed for various
ECM types. Because of their differing structure and function,
the strategy for decellularization and recellularization of each
must be accommodated for their level of complexity. Here,
we discuss how different decellularization methods have been
applied to regenerate various cell sheets, tissues, and whole
organs.
5.1. Cell Sheets. Cell sheets can be prepared and subsequently
decellularized to be used in a number of applications. They
typically consist of a single cell type that can be used alone
to facilitate regeneration of minor injuries or combined with
many sheets and structured to form complex constructs.
For example, to generate an ECM to promote periodontium
regeneration, periodontal ligament cell sheets were prepared
and then decellularized to conserve the native growth factor-,
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Table 2: Summary of ECM type treated using main decellularization strategies.
Agents and
techniques

SDS

Triton X-100
SD/DNase
CHAPS
Peracetic acid
EDTA/trypsin
Freeze-thaw

Cell sheet/tissue/organ
Fibroblast cell sheet [55], rat forearm [58],
porcine cornea [30], porcine myocardium [59],
porcine heart valve [47], porcine small
intestine (SIS) [45], porcine kidney [34],
human vein [60], rat, porcine, and human
lungs [40, 46], human heart [61]
Bovine pericardium [48], porcine kidney [34]
Porcine blood vessel [63], bovine blood vessel
[49], rat trachea [64], porcine trachea [50], rat
small intestine [51], porcine SIS [45]
Rat lung [40, 41], human and porcine lung
[40, 46]
Porcine SIS [45], porcine urinary bladder [52]
Porcine pulmonary valve [47, 53]
Fibroblast cell sheet [55], canine lumbar spinal
segment [56]

High hydrostatic
Porcine cornea [28], porcine blood vessel [23]
pressure

collagen-, and fibronectin-laden matrix [87]. Moreover, many
cell sheets derived from cartilage sections have been combined in a “sandwich model” to generate two-dimensional
cartilage constructs. In one study, 10 𝜇m decellularized cartilage slices were alternated with chondrocytes, with the cell
suspension sandwiched between the decellularized matrices,
for a total of 20 layers [82]. In another similar model, bonemarrow mesenchymal stem cells were seeded instead so they
could differentiate into chondrocytes [83]. In both cases,
cartilage constructs capable of being implanted in vivo were
formed.
Another promising application involving the creation of
blood vessels from fibroblast cell sheets emphasizes the ability
of simple decellularized matrices to form more complex
structures. In one study, fibroblast monolayer cell sheets were
prepared and rolled into vessels before being decellularized
and seeded with endothelial cells [24]. Specifically, cell sheets
were cultured for three weeks in growth media supplemented
with ascorbic acid and then rolled around mandrels of
diameters comparable to natural blood vessels. These tubular
structures were then cultured for an additional four weeks
and decellularized via hypoosmotic shock in deionized water
over one week. Next, they were placed in a rotating bioreactor
and injected with endothelial cells for four hours. Constructs
were conditioned in the bioreactor for an additional week
before undergoing mechanical testing. While the engineered
vessel’s mechanical properties were comparable to natural
blood vessels, these properties, which include burst pressure
and suture retention, decreased by 24% over three months.
These results indicate potential disadvantages for long-term
implantation. Another study utilizing fibroblast cell sheets for
blood vessel formation detailed decellularizing the matrices
and reseeding them with smooth muscle cells prior to rolling
them into cylinders [88]. Because smooth muscle cells were
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used, histamine-induced contraction was observed. Thus,
each of these methods exhibits the potential of functional,
responsive blood vessel creation using decellularized cell
sheets.
5.2. Tissues. Decellularization methods have been used on
different types of tissues either to examine the treatment
on a less complex tissue or to create a scaffold for simpler
applications. For example, adipose ECM has been utilized
in testing breast cancer treatments by providing simulated
in vivo microenvironments [89]. Additionally, adipose tissue
has been frequently decellularized and then reseeded with a
patient’s own adipose-derived stem cells in order to create
constructs used in reconstructive surgeries for structural
or cosmetic purposes [75, 76, 90]. Bone reconstruction has
also been tested using bone-derived ECM to facilitate osteogenesis or the differentiation of marrow stromal cells into
osteoblasts [91]. Advancements in this area have the potential
to reduce the need for bone grafts. Similarly, decellularization
of cartilage tissue has been performed, as it is desired for
treatments relating to joint degeneration, namely, arthritis
[56, 92]. Each of these applications highlights the benefits
of tissue decellularization to create in vitro environments for
drug testing and supplementing in vivo tissue regeneration.
In another example of adipose tissue regeneration, adipose tissue was successfully decellularized, recellularized,
and implanted in vivo. Human adipose tissue was obtained
from reconstructive surgeries and decellularized using a
protocol that first required three freeze-thaw cycles, a twoday agitation period, and two four-hour saline solution
washes of different concentrations repeated over two days.
The sample was then treated with 0.25% trypsin/EDTA for
two hours, washed, and submersed in isopropyl alcohol
overnight. Finally, the sample underwent treatment in 1%
Triton X-100 for three days and was washed in ultrapure
water for two days and PBS for one day [90]. Decellularized
ECM was seeded with human adipose-derived stem cells,
and the resultant constructs were implanted into the backs
of nude rats. Samples were then tested periodically over
eight weeks. Decellularized adipose tissue that had not yet
been recellularized was also implanted and incubated for 30
days. Results showed that the constructs did not elicit an
immunogenic response, and they promoted vascularization
and subsequent regeneration of adipose tissue.
5.3. Whole Organs. The complexity of organ function requires the most extensive decellularization and reconstruction techniques, in particular necessitating the maintenance
of the organ’s ultrastructure and vasculature. A variety of
organs have been engineered in this way and have subsequently been tested in vivo on the small animal level.
In one example, the vasculature of decellularized porcine
bladder matrices was resurfaced using epithelial progenitor
cells. These scaffolds supported reseeded bladder smooth
muscle and urothelial cells, and the resultant bladders were
successfully implanted for one to three hours in pigs [33].
The vasculature itself is also commonly utilized as a means
of injecting desired cells to repopulate the decellularized
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scaffold, as seen with the heart [42] and liver [38, 39].
Basic functionality of each organ was also observed, as
contraction was seen in the heart [42], and albumin and urea
production was seen in the liver [38, 39]. However, longterm studies have been lacking in the area of bioscaffoldproduced engineered whole organs, so the ability of the
organ to perform its function over time is necessary to
evaluate.
One particular study observed an engineered pancreas in
mice that had been achieved through perfusion decellularization [93]. The isolated mouse pancreases were injected with
0.5% SDS until they became translucent followed by 1% Triton
X-100 and a solution of Benzonase before being washed. Scaffolds were then recellularized with two types of pancreatic
cells for a culture period of five days before being implanted
for 14 days. The first type of cells, MIN-6 cells, was introduced
via the hepatic portal vein and seeded through the vasculature
in three steps. The second cell type, AR42J cells, was seeded
through the pancreatic duct. These cells successfully repopulated the pancreas, and insulin gene expression was observed
to be upregulated, indicating appropriate function. Additionally, implantation in mice revealed that the construct was
biocompatible and did not elicit a significant immunogenic
response.
Clinical applications of decellularized ECM are becoming more prevalent; however, they have been limited to
less complex tissues primarily functioning in structural or
reconstructive roles. Several FDA-approved products on the
market aimed at tissue regeneration and replacement are
derived from xenogeneic or allogeneic decellularized ECM,
including LifeCell’s AlloDerm Regenerative Tissue Matrix
(human dermal graft), DSM’s Meso BioMatrix Surgical
Mesh (porcine mesothelium), and CryoLife’s SynerGraft
(human pulmonary heart valve). The former two scaffolds
serve to facilitate cell proliferation, whereas the lattermost
product serves as a replacement for the existing structure. Furthermore, clinical trials have been carried out for
more complex structures. For example, the first tissueengineered trachea to be implanted was generated using
decellularization [31]. Although the patient’s native trachea
experienced stenosis near the interface of the engineered
construct within five years following transplantation, the
vascularized and recellularized construct remained intact and
did not provoke a significant immunogenic response [94].
While long-term clinical studies using decellularized ECM
as scaffolds are minimal, these results show their promise in
the development of more accessible treatments for a variety of
applications.

6. Outlook
While great advancements are being made in regenerative
medicine through decellularization, it is essential that protocols be further developed to optimize the process. Current
decellularization methods are beneficial in some regards but
oftentimes lack in others. Ideal methods will produce celland genetic material-free ECM that retains important structural, biochemical, and biomechanical properties crucial to
its inherent function. Several methods may be optimized in
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such a way as to achieve this balance, specifically in eliminating the components individualized to the tissue which
could cause an immunogenic response, while maintaining
those that will support and regulate the reconstruction of a
new tissue. In particular, developing methods that consist of
combined strategies with chemicals, enzymes, and mechanical techniques may improve decellularization efficiency and
limit the negative effects caused by simpler methods. This
improvement may be achieved through dynamic processes
in which parameters are adjusted over time based upon the
component in need of removal or maintenance. Thus, the
tissue may be examined and assessed at predetermined time
points throughout treatment. For example, supercritical CO2
may be utilized for cell lysis; then the ECM may undergo brief
exposure to lower concentrations of surfactants to eliminate
remnant cellular materials. Further enzymatic or wash agents
can then be applied. The goal is ultimately to administer
the minimum amount of harsh chemicals or mechanical
treatments so as to prevent unnecessary damage to the ECM’s
microstructure and ultrastructure.
By optimizing the decellularization process, tissue and
organ scaffolds derived from humans and animals may
be utilized, thus minimizing the donor-patient specificity
required to ensure compatible transplants. However, truly
bridging the gap between donors and patients in need
of transplants through bioscaffold tissue engineering will
require the development of scaled-up methods, since current
methods are usually limited to small tissues or organs. In
addition, recellularization methods will need to be improved
in order to distribute the proper cell types uniformly through
the tissue and enable sufficient nutrient and oxygen delivery
for optimal cell viability. Finally, with the continuous innovation in decellularization strategies and advancements in
uses for human induced pluripotent stem cells, off-the-shelf
tissues and organs may be made available, thereby aiding
in, and potentially eliminating, the ever-increasing need for
transplants.
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